Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a panel of eight solid-tumor cell lines in vitro

Cancer Chemotherapy and Pharmacology

Volumn 41, Issue 4, 1998, Pages 307-316

  Ma, Jianguo ^a   Maliepaard, Marc ^a,b   Nooter, Kees ^a   Boersma, Antonius W M ^a   Verweij, Jaap ^a   Stoter, Gerrit ^a   Schellens, Jan H M ^a,b  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Cisplatin; In vitro; Schedule; SN 38; Synergy; Topoisomerase I; Topotecan

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CISPLATIN; DNA TOPOISOMERASE INHIBITOR; TOPOTECAN;

ARTICLE; CELL CYCLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; ENZYME ACTIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SOLID TUMOR; TUMOR CELL LINE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CISPLATIN; DNA ADDUCTS; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; HUMANS; TOPOTECAN; TUMOR CELLS, CULTURED;

EID: 0031965435     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050744     Document Type: Article

References (45)

1. Ali-Osman F, Berger MS, Rajagopal S, Spence A, Livingston RB (1993) Topoisomerase II inhibition and altered kinetics of formation and repair of nitrosourea and cisplatin-induced DNA interstrand cross-links and cytotoxicity in human glioblastoma cells. Cancer Res 53: 5663
2. Andoh T, Okada K (1995) Drug resistance mechanisms of topoisomerase I drugs. Adv Pharmacol 29B: 93
3. Bedford P, Fichtinger-Schepman AMJ, Shellard SA, Walker MC, Masters JRW, Hill BT (1998) Differential repair of platinum-DNA adducts in human bladder and testicular tumor continuous cell lines. Cancer Res 48: 3019
4. Bergerat J-P, Barlogie B, Göhde W, Johnston DA, Drewinko B (1979) In vitro cytokinetic response of human colon cancer cells to cis-dischlorodiammineplatinum(II). Cancer Res 39: 4356
5. Bradford M (1976) A rapid and sensitive method for the quantification of microgram quantities of protein using the principle of protein-dye binding. Anal Biochem 72: 248
6. Chou T-C, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effect of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27
7. Chou T-C, Motzer RJ, Tong Y, Bosl GJ (1994) Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst 20: 1517
8. Jong S, Zijlstra JG, Timmer-Bosscha H, Mulder NH, Vries EGE de (1986) Detection of DNA cross-links in tumor cells with the ethidium bromide fluorescence assay. Int J Cancer 37: 557
9. Del Bino G, Skierski JS, Darzynkiewicz Z (1990) Diverse effects of camptothecin, an inhibitor of topoisomerase I, on the cell cycle of lymphocytic (L1210, MOLT-4) and myelogenous (HL-60, KG1) leukemic cells. Cancer Res 50: 5746
10. Del Bino G, Skierski JS, Darzynkiewicz Z (1991) The concentration-dependent diversity of effects of DNA topoisomerase I and II inhibitors on the cell cycle of HL-60 cells. Exp Cell Res 195: 485
11. Dijt FJ, Fichtinger-Schepman AMJ, Berends F, Reedijk J (1988) Formation and repair of cisplatin-induced adducts to DNA in cultured normal and repair-deficient human fibroblasts. Cancer Res 48: 6058
12. Eder JP, Teicher BA, Holden SA, Cathcart KNS, Schnipper LE (1990) Ability of four potential topoisomerase II inhibitors to enhance the cytotoxicity of cis-diamminedichloroplatinum(II) in Chinese hamster ovary cells and in an epipodophyllotoxin-resistant subline. Cancer Chemother Pharmacol 26: 423
13. Ellis GK, Crowley J, Livingston RB, Goodwill JW, Hutchins L, Allen A (1991) Cisplatin and novobiocin in the treatment of non-small cell lung cancer. A Southwest Oncology Group study. Cancer 67: 2969
14. Estman A, Schulte N (1988) Enhanced DNA repair as a mechanism of resistance to cis-diamminedichloroplatinum(II). Biochemistry 27: 4730
15. Hertzberg RP, Jo Caranfa M, Holden KG, et al (1989) Modification of the hydroxylacton ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. J Med Chem 32: 715
16. Hill BT, Scanlon KJ, Hansson J, Harstrick A, Pera M, Fichtinger-Schepman AMJ, Shellard SA (1994) Deficient repair of cisplatin-DNA adducts identified in human testicular teratoma cell lines established from tumours from untreated patients. Eur J Cancer 30A: 832
17. Hochster H, Liebes L, Speyer J, Sorich J, Taubes B, Oratz R, Wernz J, Chachoua A, Raphael B, Vinci RZ, Blum RH (1994) Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen. J Clin Oncol 12: 553
18. Inaba M, Mitsuhashi J, Kawada S, Nakano H (1994) Different modes of cell-killing action between DNA topoisomerase I and II inhibitors revealed by kinetic analysis. Jpn J Cancer Res 85: 187
19. Johnson SW, Swiggard PA, Handel LM, Brennan JM, Godwin AK, Ozols RF, Hamilton TC (1994) Relationship between platinum-DNA adduct formation and removal and cisplatin cytotoxicity in cisplatin-sensitive and -resistant human ovarian cancer cells. Cancer Res 54: 5911
20. Juan C-C, Hwang J, Liu AA, Whang-Peng J, Knutsen T, Huebner K, Croce CM, Zhang H, Wang JC, Liu LF (1988) Human DNA topoisomerase I is encoded by a single-copy gene that maps to chromosome region 20q12-13.2. Proc Natl Acad Sci USA 85: 8910
21. Kano Y, Suzuki K, Akutsu M, Suda K, Inoue Y, Yoshida M, Sakamoto S, Miura Y (1992) Effects of CPT-11 in combination with other anti-cancer agents in culture. Int J Cancer 50: 604
22. Kijima T, Kubota N, Nishio K (1994) Establishment of a CPT-11-resistant human ovarian cancer cell line. Anticancer Res 14: 799
23. Krishan A (1975) Rapid flow cytofluorometric analysis of mammalian cell cycle by propidium iodide staining. J Cell Biol 66: 188
24. Loehrer S, Einhorn ADJ (1984) Diagnosis and treatment - drugs five years later: cisplatin. Ann Intern Med 100: 704
25. Lopez R, Peters GJ, Smitskamp-Wilms E, Virizuela JA, Ark-Otte J van, Pinedo HM, Giaccone G (1994) In vitro sequence-dependent synergistic effect of suramin and camptothecin. Eur J Cancer 30A: 1670
26. Ma J, Verweij J, Kolker HJ, Ingen HE van, Stoter G, Schellens JHM (1994) Pharmacokinetic-dynamic relationship of cisplatin in vitro: simulation of an i.v. bolus and 3 h and 20 h infusion. Br J Cancer 69: 858
27. Ma J, Maliepaard M, Kolker HJ, Verweij J, Schellens JHM (1997) Abrogated energy-dependent uptake of cisplatin in a cisplatin-resistant subline of the human ovarian cancer cell line IGROV-1. Cancer Chemother Pharmacol (in press)
28. Masumoto N, Nakano S, Esaki T, Fujishima H, Tatsumoto T, Niho Y (1995) Inhibition of cis-diamminedichloroplatinum(II)-induced DNA interstrand cross-link removal by 7-ethyl-10-hydroxy-camptothecin in HST-1 human squamous-carcinoma cells. Int J Cancer 62: 70
29. Masumoto N, Nakano S, Esaki T, Tatsumoto T, Fujishima H, Baba E, Nakamura M, Niho Y (1995) Sequence-dependent modulation of anticancer drug activities by 7-ethyl-10-hydroxycamptothecin in an HST-1 human squamous carcinoma cell line. Anticancer Res 15: 405
30. Miller SA, Dykes DD, Polesky HF (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16: 1215
31. Mistry P, Kelland LR, Abel G, Sidhal S, Harrap KR (1991) The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight ovarian carcinoma cell lines. Br J Cancer 64: 215
32. Musuda H, Ozols RF, Lai G-M, Fojo A, Rotherberg M, Hamilton TC (1988) Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum(II) in human ovarian cancer cell lines. Cancer Res 48: 5713
33. Plooy ACM, Dijk M van, Lohman PHM (1984) Induction and repair of DNA cross-links in Chinese hamster ovary cells treated with various platinum coordination compounds in relation to platinum binding to DNA, cytotoxicity, mutagenicity, and antitumor activity. Cancer Res 44: 2043
34. Reed E, Sauerhoff S, Poirier MC (1988) Quantitation of platinum-DNA binding after therapeutic levels of drug exposure - a novel use of graphite furnace spectrometry. Atom Spectrosc 9: 93
35. Rowinsky EK, Adjei A, Donehower RC, Gore SD, Jones RJ, Burke PJ, Cheng Y, Grochow LB, Kaufmann SH (1994) Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia. J Clin Oncol 12: 2193
36. Scher R, Green LF, Kosierowski R, Simmonds M, Engstrom PF, O'Dwyer PJ (1994) Phase II trial of topotecan in advanced pancreatic cancer. Proc NCI-EORTC Symp New Drugs Cancer Ther 8: A463
37. Schmidt W, Chaney SG (1993) Role of carrier ligand in platinum-resistance of human carcinoma cell lines. Cancer Res 53: 799
38. Slichenmyer WJ, Rowinsky EK, Grochow LB, Kaufmann SH, Donehower RC (1994) Camptothecin analogues: studies from The Johns Hopkins Oncology Center. Cancer Chemother Pharmacol 34: S53
39. Sorenson CM, Eastman A (1988) Influence of cis-diamminedichloroplatinum(II) on DNA synthesis and cell cycle progression in excision repair proficient and deficient Chinese hamster ovary cells. Cancer Res 48: 6703
40. 2 phase and cell death induced by cisplatin. J Natl Cancer Inst 82: 749
41. Stoter G, Koopman A, Vendrik CPJ, Struyvenberg A, Sleyfer DT, Willemse PHB, Schraffordt Koops H, Oosterom AT van, Bokkel-Huinink WW ten, Pinedo HM (1989) Ten-year survival and late sequelae in testicular cancer patients treated with cisplatin, vinblastine and bleomycin. J Clin Oncol 7: 1099
42. Tanizawa A, Fujimori A, Fujimori Y, Pommier Y (1994) Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J Natl Cancer Inst 86: 836
43. Wang JC (1985) DNA topoisomerases. Annu Rev Biochem 54: 665
44. Zee AGJ van der, Hollema H, Jong S de, Boonstra H, Gouw A, Willemse PHB, Zijlstra JG, Vries EGE de (1991) P-glycoprotein expression and DNA topoisomerase I and II activity in benign tumors of the ovary and in malignant tumours of the ovary, before and after platinum/cyclophosphamide chemotherapy. Cancer Res 51: 5915
45. Zhen W, Link CJ Jr, O'Connor PM, Reed E, Parker R, Howell SB, Bohr VA (1992) Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines. Mol Cell Biol 12: 3689